Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

In this trial, both drugs helped improve these health markers, but tirzepatide’s added benefits could make it the top choice for many people with obesity. Still, not every patient will need the ...

The tirzepatide group had more injection-site reactions than the semaglutide group, which is consistent with other SURMOUNT trials. 14,20 In the current trial, no participants were reported to ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference. Fox News Media Fox Business ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

Patients who remained on treatment, especially at higher doses or on tirzepatide, ... (GLP-1) receptor agonists for obesity treatment appear less effective than in clinical trials, ...

Citation: Tirzepatide produces clinically meaningful weight loss for at least 3 years in non-diabetic overweight adults: Trial (2025, April 14) retrieved 20 July 2025 from https://medicalxpress ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...